(7-溴-1-乙基-1H-咪唑并[4,5-c]吡啶-2-基)乙腈 | 842143-97-9

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: (7-溴-1-乙基-1H-咪唑并[4,5-c]吡啶-2-基)乙腈
• 英文名称: 2-(7-bromo-1-ethylimidazo[4,5-c]pyridin-2-yl)acetonitrile
• 英文别名: (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile；2-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile
• CAS: 842143-97-9
• 化学式: C₁₀H₉BrN₄
• 分子量: 265.112
• InChiKey: IQHHQMKFGJJRMZ-UHFFFAOYSA-N

物化性质

• 沸点：
  453.0±35.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  54.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  (7-溴-1-乙基-1H-咪唑并[4,5-c]吡啶-2-基)乙腈 在 sodium nitrite 、 sodium hydroxide 、 羟胺 作用下， 以 甲醇 、 水 为溶剂， 反应 4.0h， 以67%的产率得到4-(7-bromo-1-ethylimidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-amine
  参考文献：
  名称：

  [EN] INHIBITORS OF Akt ACTIVITY
  [FR] INHIBITEURS DE L'ACTIVITE DE AKT

  摘要：

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物用作蛋白激酶B活性的抑制剂，并用于治疗癌症和关节炎。

  公开号：

  WO2005011700A1
• 作为产物：
  描述：

  (3-溴-5-硝基-吡啶-4-基)-乙基-胺 在 sodium dithionite 作用下， 以 乙醇 为溶剂， 生成 (7-溴-1-乙基-1H-咪唑并[4,5-c]吡啶-2-基)乙腈
  参考文献：
  名称：

  (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

  摘要：

  The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases. (c) 2005 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.05.020

文献信息

• [EN] CANCER TREATMENT METHOD<br/>[FR] METHODE DE TRAITEMENT DU CANCER
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005046678A1

  公开（公告）日：2005-05-26

  The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.

  本发明涉及一种治疗哺乳动物癌症的方法以及在这种治疗中有用的药物组合。具体而言，该方法涉及一种癌症治疗方法，其中向患有癌症的哺乳动物施用一种erb家族抑制剂和一种PI3K和/或Akt抑制剂。
• [EN] MICROBIOCIDAL 4-(IMIDAZO[4,5-C]PYRIDIN-2-YL)-1,2,5-OXADIAZOL-3- AMINE COMPOUNDS HAVING AN OXIME GROUP IN POSITION 7<br/>[FR] COMPOSÉS 4-(IMIDAZO[4,5-C]PYRIDIN-2-YL)-1,2,5-OXADIAZOL-3-AMINE MICROBIOCIDES COMPRENANT UN GROUPE OXIME EN POSITION 7
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2016038143A1

  公开（公告）日：2016-03-17

  The present invention provides compounds of formula (I) wherein Y1, Y2, Υ3, Υ4 and Υ5 are as defined in the claims. The invention further relates to compositions which comprise these compounds and to their use in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.

  本发明提供了式（I）的化合物，其中Y1、Y2、Υ3、Υ4和Υ5如权利要求所定义。本发明还涉及包含这些化合物的组合物，并且涉及它们在农业或园艺中的使用，用于控制或预防植物被植物病原微生物，特别是真菌的侵染。
• Inhibitors of Akt Activity
  申请人：Heerding Dirk A.

  公开号：US20080255143A1

  公开（公告）日：2008-10-16

  Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

  发明了新型的1H-咪唑[4,5-c]吡啶-2-基化合物，这些化合物可用作蛋白激酶B活性抑制剂，并用于癌症和关节炎的治疗。
• Cancer treatment method
  申请人：Dev Kumar Inderjit

  公开号：US20070161665A1

  公开（公告）日：2007-07-12

  The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from cancer.

  本发明涉及一种治疗哺乳动物癌症的方法，以及在这种治疗中有用的药物组合。具体而言，该方法涉及一种癌症治疗方法，包括向患有癌症的哺乳动物施用erb家族抑制剂和PI3K和/或Akt抑制剂。
• Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3<i>S</i>)-3-piperidinylmethyl]oxy}-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase
  作者：Dirk A. Heerding、Nelson Rhodes、Jack D. Leber、Tammy J. Clark、Richard M. Keenan、Louis V. Lafrance、Mei Li、Igor G. Safonov、Dennis T. Takata、Joseph W. Venslavsky、Dennis S. Yamashita、Anthony E. Choudhry、Robert A. Copeland、Zhihong Lai、Michael D. Schaber、Peter J. Tummino、Susan L. Strum、Edgar R. Wood、Derek R. Duckett、Derek Eberwein、Victoria B. Knick、Timothy J. Lansing、Randy T. McConnell、ShuYun Zhang、Elisabeth A. Minthorn、Nestor O. Concha、Gregory L. Warren、Rakesh Kumar

  DOI：10.1021/jm8004527

  日期：2008.9.25

  Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC 50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3beta. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3beta phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.